Hematuria in a 38-Year-Old Patient

Poll

A 38-year-old man presents with hematuria. A kidney mass is detected by imaging. Based on the shown biopsy, what is your diagnosis?

A 38-year-old man presents with hematuria. A kidney mass is detected by imaging.

Based on the shown biopsy, what is your diagnosis?

A. Metastatic small-cell carcinoma
B. Primary small-cell carcinoma of the kidney
C. Primary primitive neuroectodermal tumor
D. Renal cell carcinoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Related Content
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 13th 2025
Article
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
September 13th 2025
Podcast
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

Roman Fabbricatore
September 13th 2025
Article
Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
September 13th 2025
Podcast
Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
September 13th 2025
Article
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
September 13th 2025
Article